In order to control the expression of Sortilin/NTSR3 and its soluble counterpart, regarding their positive or negative behavior in the development of numerous pathologies, the use of specific inhibitors of the proteins, their unknown receptors, and/or their associated co-receptors would ameliorate treatments, particularly in cancers. This evidence concerns the gene AQP1 and cancer.